{"prompt": "['1. BACKGROUND / RATIONALE', '7', 'RATIONALE, SIGNIFICANCE, AND JUSTIFICATION', '9', 'ASSESSMENT OF OUTCOME/HYPOTHESIS', '9', '3. EXPECTED RISKS/BENEFITS', '10', '3.1 Expected Risks', '10', '4. ELIGIBILITY', '11', '4.1 Study Setting Description', '11', '4.2 Study Sample Description', '11', '4.3 Justification when a sample includes vulnerable populations or excludes certain', 'populations', '11', '4.4 Participant Inclusion Criteria', '11', '4.5 Participant Exclusion Criteria', '12', '4.6 Participant Withdrawal Criteria', '12', '5. STUDY DESIGN', '12', '5.1 Study Design', '12', '5.2 Number of Participants/Assignment to Treatment Groups', '13', '5.3 Duration of Study and Study Timeline', '13', '5.4', 'Length of Participation', '13', '6.1 Participant Identification and Recruitment Procedures', '13', '6.2 Procedures for Informed Consent', '14', '6.3 Procedures for Participant Screening', '14', '6.4 Procedures for Participant Enrolment /Allocation /Randomization', '14', '6.5 Procedures for Participant Retention', '15', '7. STUDY PROCEDURES', '15', '7.1 Time and Events Schedule', '15', '7.2 Description of Study Procedures, Assessments and Participant Activities', '15', 'Physical and Cognitive Assessment:', '15', 'Biomarker Assessment:', '16', 'Neuroimaging:', '17', 'ODDBALL paradigm:', '17', 'FLANKER task:', '18', 'Behaviour Measure (Driving Simulator):', '18', 'Aerobic and Balance Retraining Program:', '19', '4']['RP-506-07112017', 'V 1.5: November 30th, 2018', '8. DATA MANAGEMENT', '20', '8.1 Data Collection', '20', '8.2 Data Management', '21', '9. SPECIMEN MANAGEMENT', '22', '10. DATA / SPECIMEN ANALYSIS', '22', '11. STATISTICAL CONSIDERATIONS', '23', '11.1 Sample Size Calculation', '23', '11.2 Statistical Analysis', '23', '12. OTHER STUDY ADMINISTRATION CONSIDERATIONS', '24', '12.1 Concomitant use of medications or interventions during the course of the study', '24', '12.2 Allocation sequence generation and concealment mechanism', '24', '12.3 Blinding Procedures', '24', '12.4 Premature discontinuation or termination of the study', '24', '12.5 Ancillary and post-trial care', '24', '13. QUALITY CONTROL AND QUALITY ASSURANCE', '24', '13.1 Data Integrity Measures', '25', '13.2 Training Study Staff', '25', '13.3 Auditing and Monitoring', '25', '14. REGULATORY CONSIDERATIONS', '25', '14.1 Participant privacy and confidentiality', '25', '14.2 Ethical Review', '26', '14.3 Scientific Review', '26', '14.4 Institutional Review', '26', '14.5 Clinical Trial Registration', '26', '14.6 Retention of Study Documents', '26', '14.7 Data Monitoring Committee', '26', '14.8 Unanticipated Problems', '26', '14.9 Publication of Data and Protection of Trade Secrets', '27', '14.10 Dissemination', '27', '14.11 Declaration of interests', '27', '15. References', '28', '5', 'Multi-modal Evaluation of a Physical Intervention Approach to Treating Persistent', 'Post-Concussive Symptoms']['16. APPENDICES', '31', '16.1 Recruitment materials', '31', '16.2 Informed consent materials', '34', '16.3 Screening checklists', '48', '16.4 Data abstraction form', '50', '16.5 International Physical Activity Questionnaire', '51', '16.6 Study budget', '54', '6']\n\n###\n\n", "completion": "END"}